Top 5 Pharma Company Signs 5-Year Multi-million Dollar Agreement for OmniComm System's TrialOne Application Suite


Company News Release

TrialOne to Automate Global Phase I Clinic Operations

OmniComm Systems, Inc. (OTC: OMCM.OB), one of the fastest growing companies in the EDC marketplace, today announced that its TrialOne® suite of applications has been chosen by a top 5 pharmaceutical company to automate their global clinical trial operations and processes in all their early-phase clinics.

TrialOne is a web-based, mobile, clinic automation solution designed specifically for early-phase research to facilitate recruitment, appointment scheduling, study building and design, screening, source data capture, sample tracking and reporting. TrialOne offers time-based data entry and integration with bar-code scanners and printers and biomedical monitoring devices to automate data, sample collection and processing.  The flexible and configurable workflow streamlines operational and data management processes, while enhancing protocol compliance and data quality.

The clinics will be implementing the entire TrialOne suite, including Sample Tracking, Direct Data Capture, and Subject Recruitment & Screening and the implementation will be centralized and hosted by OmniComm and accessed via the web to accommodate a standardized workflow across all clinics. 

“Traditionally, implementing a centralized, automated solution across global business units has been problematic for the Phase I industry,” said Randy Smith, CTO of OmniComm. “Most of the solutions designed for Phase I Clinics do not support a centralized, web-based approach and therefore clinics have been forced to manage their disparate sites with local implementations, making collaboration and standardization extremely difficult.  OmniComm’s TrialOne application employs a high availability architecture with built in multi-geographic redundancy to mitigate potential network outages and provide for business continuity.”  OmniComm Systems offers the only fully-validated and hosted, turnkey solution for standardizing and centralizing clinic operations.



Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Related Videos
Greg Ball, Founder, ASAP Process Consulting image credit screen shot from video
Janice Chang, CEO, TransCelerate BioPharma @ video screenshot.
Related Content
© 2024 MJH Life Sciences

All rights reserved.